2月6日，针对近日部分媒体关于精神专科医院涉嫌违规问题的报道中，将襄阳恒泰康医院有限公司（下 称"襄阳恒泰康医院"）与爱尔眼科及其实际控制人陈邦直接关联的情况，爱尔眼科紧急回应，并对相关 股权关系及企业边界作出说明。 爱尔眼科方面表示，相关报道中部分表述存在概念混用，可能引发公众误解。 据此前报道，湖北多家精神专科医院被曝可能存在虚构诊疗项目、套取医保资金等问题，涉嫌违规，涉 事医院包括襄阳融诚医院、襄阳宏安医院、襄阳恒泰康医院、宜昌夷陵康宁精神病医院等。 关于襄阳恒泰康医院的股权结构及层级问题，爱尔眼科方面回应称，襄阳恒泰康医院并非爱尔眼科所属 企业。该公司为爱尔眼科控股股东——爱尔医疗投资集团有限公司（下称"爱尔医疗投资集团"）与其他 投资方合资设立的四级子公司，不属于爱尔眼科上市公司合并报表范围。作为投资人之一，爱尔医疗投 资集团及陈邦并不直接参与襄阳恒泰康医院的经营管理。 目前，作为股东方，爱尔医疗投资集团紧急督促襄阳恒泰康医院实际经营方、管理层全面核查相关情 况，并全面配合相关调查。 知情人士向上海证券报记者透露，爱尔医疗投资集团为持股平台，核心以投资爱尔眼科为主，聚焦眼科 诊疗领域。"这些年来，伴 ...

Core Insights - Jin Yu Medical (金域医学) reported a significant decline in revenue, with a 15.81% year-on-year decrease, resulting in total revenue of 7.19 billion yuan for 2024 [5][7] - The company faced challenges with accounts receivable, which accounted for 42.39% of total assets, amounting to 4.396 billion yuan [7] - Other medical companies, including Meinian Health (美年健康), He Shi Eye Hospital (何氏眼科), and BGI Genomics (华大基因), also reported declines in revenue and net profit, indicating a broader trend in the industry [5][13] Financial Performance - Jin Yu Medical's net profit for 2024 was -381 million yuan, a decrease of 159.26% compared to the previous year [5] - BGI Genomics reported a revenue of 3.867 billion yuan, down 11% year-on-year, with a net profit of -903 million yuan [5][13] - Meinian Health's data resource entry amounted to 9.352 million yuan, with a focus on developing health management products [15] Data Resource Integration - Jin Yu Medical disclosed data resource integration amounting to 7.0083 million yuan, with 3.3544 million yuan classified as development expenses and 3.6538 million yuan recognized as intangible assets [1] - BGI Genomics led the industry with a data resource entry of 9.6217 million yuan, primarily from external data governance platforms [13] - He Shi Eye Hospital reported 905,100 yuan in data resources, all classified as self-developed intangible assets [14] Market Trends - The medical industry is increasingly focusing on data-driven precision medicine, with companies like BGI Genomics and He Shi Eye Hospital investing in comprehensive data management systems [13][14] - Jin Yu Medical is actively participating in the data circulation market, having launched 11 data products for trading and establishing a trusted data space in Guangzhou [9][10] - The trend towards integrating data resources into healthcare solutions is expected to continue, with companies exploring innovative applications in medical decision-making and patient care [14][15]